Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant IL-2 + IFN-alpha in RCC (POLAR 01)
NCT00502034Phase 3Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jul 1994
- Primary completion
- Apr 2007
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aldesleukin and interferon alfa-2a in renal cell carcinoma (RCC) (2 arms), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Recurrence-free survival. Started Jul 1994; status: completed.
02
Drugs
aldesleukininterferon alfa-2a
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00502034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00502034.